Lemborexant
Dayvigo (lemborexant) is a small molecule pharmaceutical. Lemborexant was first approved as Dayvigo on 2020-04-07. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against orexin receptor type 2 and orexin/Hypocretin receptor type 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Dayvigo
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dayvigo | New Drug Application | 2023-12-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| sleep initiation and maintenance disorders | — | D007319 | F51.01 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LEMBOREXANT, DAYVIGO, EISAI INC | |||
| 2026-04-20 | M-293 | ||
| 2025-04-07 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 4 | 2 | 4 | 2 | 3 | 15 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 3 | — | 1 | — | 4 |
| Dementia | D003704 | EFO_0003862 | F03 | — | 1 | — | 1 | — | 2 |
| Circadian rhythm sleep disorders | D020178 | — | G47.2 | — | 1 | — | 1 | — | 2 |
| Dyssomnias | D020920 | — | — | — | — | — | 1 | — | 1 |
| Parasomnias | D020447 | — | G47.5 | — | — | — | 1 | — | 1 |
| Syndrome | D013577 | — | — | — | — | — | 1 | — | 1 |
| Frontotemporal dementia | D057180 | HP_0002145 | G31.0 | — | — | — | 1 | — | 1 |
| Primary progressive aphasia | D018888 | EFO_0009053 | G31.01 | — | — | — | 1 | — | 1 |
| Pick disease of the brain | D020774 | EFO_0003096 | G31.01 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep | D012890 | GO_0030431 | — | — | 1 | 2 | — | — | 3 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | — | 1 | — | — | 1 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Analgesia | D000698 | — | — | 1 | 1 | — | — | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | 1 | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 1 | — | — | — | 1 |
| Drug interactions | D004347 | — | — | 1 | 1 | — | — | — | 1 |
| Sleep wake disorders | D012893 | — | G47 | — | 1 | — | — | — | 1 |
| Delirium | D003693 | — | R41.0 | — | 1 | — | — | — | 1 |
| Feasibility studies | D005240 | — | — | — | 1 | — | — | — | 1 |
| Cardiac surgical procedures | D006348 | — | — | — | 1 | — | — | — | 1 |
| Hospital mortality | D017052 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 10 | — | — | — | — | 10 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 2 | — | — | — | — | 2 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | 2 | — | — | — | — | 2 |
| Apnea | D001049 | HP_0002104 | R06.81 | 2 | — | — | — | — | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | 1 | — | — | — | — | 1 |
| Respiration disorders | D012120 | — | J00-J99 | 1 | — | — | — | — | 1 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | — | 1 | 1 |
| Traumatic stress disorders | D040921 | — | — | — | — | — | — | 1 | 1 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lemborexant |
| INN | lemborexant |
| Description | Lemborexant, sold under the brand name Dayvigo, is an orexin antagonist medication which is used in the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults. The medication is taken by mouth.
|
| Classification | Small molecule |
| Drug class | Orexin receptor antagonist; Hypnotic; Sedative |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ncc(OC[C@@]2(c3cccc(F)c3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1 |
Identifiers
| PDB | — |
| CAS-ID | 1369764-02-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545367 |
| ChEBI ID | — |
| PubChem CID | 56944144 |
| DrugBank | DB11951 |
| UNII ID | 0K5743G68X (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 487 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
730 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use